Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors

BACKGROUND: Dosing schemes of pembrolizumab (anti-programmed cell death protein 1 monoclonal antibody) are solely based on pharmacokinetic (PK) modelling derived from phase I–III trials. The current study aimed to determine factors affecting PK and its relationship with clinical outcome in the real-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Hurkmans, Daan P., Sassen, Sebastiaan D.T., de Joode, Karlijn, Putter, Lisanne, Basak, Edwin A., Wijkhuijs, Annemarie J.M., Joerger, Markus, Debets, Reno, Koch, Birgit C.P., Van der Leest, Cor H., Schreurs, Marco W.J., van der Veldt, Astrid A.M., Aerts, Joachim G.J.V., Mathijssen, Ron H.J., Koolen, Stijn L.W.
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8183294/
https://ncbi.nlm.nih.gov/pubmed/34088739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002344
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados